Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 May 28.

Published in final edited form as: Leukemia. 2018 Feb 22;32(9):1932–1947. doi: 10.1038/s41375-018-0062-8

Fig. 4 — Increased expression of costimulatory and activation markers on XBP1-CTL with ACY241 treatment. XBP1 antigen-specific CTL were generated from HLA-A2⁺ normal donors’ CD3⁺ T cells by repeated weekly stimulation with a cocktail of heteroclitic unspliced XBP1_184-192 (YISPWILAV) and spliced XBP1 SP_196–204 (YLFPQLISV) peptides. After the fourth cycle of peptides stimulation, CTL were treated with ACY241 for 48 h and evaluated for their cell viability and cell surface profile. The frequency of CD28⁺ or CD38⁺ single positive CTL, as well as CD28⁺CD38⁺ double positive CTL, was enhanced in a dose-dependent manner (Fig. 4a). CD28 co-stimulatory molecule expression on the XBP1-CTL was also increased in a time-dependent manner (Fig. 4b) by ACY241 treatment. The expression levels (MFI) and frequency of cells expressing CD40L, 41BB and 0X40 were increased upon ACY241 treatment in a dose-dependent manner (Fig. 4c) (p < 0.05)

Fig. 4 — Increased expression of costimulatory and activation markers on XBP1-CTL with ACY241 treatment. XBP1 antigen-specific CTL were generated from HLA-A2⁺ normal donors’ CD3⁺ T cells by repeated weekly stimulation with a cocktail of heteroclitic unspliced XBP1_184-192 (YISPWILAV) and spliced XBP1 SP_196–204 (YLFPQLISV) peptides. After the fourth cycle of peptides stimulation, CTL were treated with ACY241 for 48 h and evaluated for their cell viability and cell surface profile. The frequency of CD28⁺ or CD38⁺ single positive CTL, as well as CD28⁺CD38⁺ double positive CTL, was enhanced in a dose-dependent manner (Fig. 4a). CD28 co-stimulatory molecule expression on the XBP1-CTL was also increased in a time-dependent manner (Fig. 4b) by ACY241 treatment. The expression levels (MFI) and frequency of cells expressing CD40L, 41BB and 0X40 were increased upon ACY241 treatment in a dose-dependent manner (Fig. 4c) (p < 0.05)